(Alliance News) - Summit Therapeutics PLC on Thursday said results from the second phase of clinical trial of ridinilazole in C difficile infection showed improvements in patient quality of life.
C difficile infection is caused by an infection of the colon by the bacterium, which produces toxins that cause inflammation and severe diarrhoea, and in the most serious cases can be fatal.
The antibiotics development company said the second phase clinical trial - called CoDIFy - evaluated ridinilazole compared to vancomycin in 100 patients with C difficile infection.
Overall, fewer patients treated with ridinilazole than patients treated with vancomycin reported any problems over the time points in four of the five domains: mobility, self-care, usual activities and pain.
Summit Therapeutics noted that patients in both cases reported problems with anxiety and depression at baseline, however, the number of patients treated with ridinilazole reporting problems in this measure decreased throughout the timepoints. By day 40, patients treated with ridinilazole had improved "significantly more" than vancomycin in anxiety and depression, Summit Therapeutics highlighted.
While both treatment arms showed significant improvements in pain and discomfort, by day ten, numerically fewer patients treated with ridinilazole reported issues than those treated with vancomycin.
"Our phase 2 clinical trial documented significant early and longer-term improvements in patient quality of life over the current standard of care," said David Roblin, president of research & development at Summit.
"These findings suggest the benefits of treatment with ridinilazole goes beyond the clinical benefits seen in the phase 2 clinical trial, with our precision antibiotic also improving the overall wellbeing of the patient," added Roblin.
Summit Therapeutics shares were trading 4.6% higher in London on Thursday at 26.67 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
